Article
Lab Invest 2000, 80:745–757
Metallothionein Inhibits Myocardial Apoptosis in Copper-Deficient Mice: Role of Atrial Natriuretic Peptide
This research was supported in part by U.S. Department of Agriculture grant #9604531, National Institutes of Health grants HL59225 and CA68125, American Heart Association Established Investigator Award (9640091N), and Jewish Hospital Foundation, Louisville, Kentucky.
Mention of a trademark or proprietary product does not constitute a guarantee or warranty of the product by the U.S. Department of Agriculture and does not imply its approval to the exclusion of other products that may be suitable.
The U.S. Department of Agriculture, Agricultural Research Service, Northern Plains Area, is an equal opportunity/affirmative action employer and all agency services are available without discrimination.
Y James Kang1,2,3, Zhan-Xiang Zhou1, Huiyun Wu1, Guang-Wu Wang1, Jack T Saari5 and Jon B Klein1,4
- 1Department of Medicine, University of Louisville, Louisville, Kentucky
- 2Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky
- 3Department of Jewish Hospital, Heart and Lung Institute, Louisville, Kentucky
- 4Department of Veterans Affairs Medical Center, Louisville, Kentucky
- 5US Department of Agriculture (JTS), Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, North Dakota
Correspondence: Dr. Y. James Kang, Department of Medicine, University of Louisville School of Medicine, 511 S. Floyd St., MDR 530, Louisville, KY 40292. Fax: 502-852-6904; E-mail: yjkang01@athena.louisville.edu
Received 15 February 2000.
Abstract
Dietary copper restriction causes heart hypertrophy in animal models. Several studies have indicated that this cardiomyopathy is mediated by oxidative stress. Metallothionein (MT), a low molecular weight and cysteine-rich protein, functions in protecting the heart from oxidative injury. We therefore used a cardiac-specific MT-overexpressing transgenic mouse model to test the hypothesis that MT inhibits copper deficiency-induced heart hypertrophy. Dams of both transgenic pups and non-transgenic littermates were fed a copper-adequate or copper-deficient diet, starting on the fourth day post-delivery, and the weanling mice were continued on the dams' diets until they were killed. Heart hypertrophy developed in copper-deficient pups by the fourth week of the combined pre- and post-weaning feeding and aggressively progressed until the end of the experiment (6 weeks). MT overexpression did not prevent the occurrence of heart hypertrophy, but inhibited the progression of this cardiomyopathy, which correlated with its suppression of cardiac lipid peroxidation. Corresponding to the progression of heart hypertrophy, myocardial apoptosis and atrial natriuretic peptide (ANP) production in the left ventricle were detected in non-transgenic copper-deficient mice; these effects were significantly suppressed in transgenic copper-deficient mice. Measurement of apoptosis by TUNEL assay and Annexin V-FITC confocal microscopy in primary cultures of cardiomyocytes revealed that ANP was largely responsible for the myocyte apoptosis and that MT inhibited ANP-induced apoptosis. The data clearly demonstrate that elevation of MT in the heart inhibits oxidative injury and suppresses the progression of heart hypertrophy in copper deficiency, although it does not block its initiation. The results suggest that MT inhibits the transition from heart hypertrophy to failure by suppressing apoptosis through inhibition of both cardiac ANP production and its apoptotic effect.
